miR-1296 in Human Cancers: Context-Dependent Tumor Suppressor and Oncogene Orchestrated by ceRNA Networks

Abnormal regulation of microRNA (miRNA) production is increasingly recognized as a hallmark of cancer development. Genetic alterations, disrupted transcriptional control, and deficiencies in processing machinery all contribute to changes in miRNA levels. Depending on the cellular environment, a single miRNA may act either in favor of tumor growth or as a barrier against malignancy. These small RNAs influence key oncogenic features, including uncontrolled cell division, suppression of growth-inhibitory pathways, evasion of programmed cell death, metastatic spread, and angiogenesis. Because of this broad impact, numerous studies have explored the potential of miRNAs as biomarkers for early diagnosis and prognosis, although further validation is still required before clinical translation. Among these regulators, hsa-miR-1296 has recently gained attention. Both strands of its precursor, miR-1296-5p and miR-1296-3p, are involved in modulating multiple signaling cascades across different tumor types. Depending on tissue context, miR-1296 can function as either a tumor suppressor or, less frequently, as an oncogenic factor by targeting genes central to cell-cycle progression, migration, invasion, and therapy resistance. Evidence from breast, lung, liver, colorectal, gastric, prostate, and bone cancers shows that miR-1296 interacts with networks of protein-coding genes and noncoding RNAs, shaping tumor behavior and influencing patient outcomes. Relevant studies were identified through searches in PubMed and Scopus databases up to 2025, focusing on experimental and clinical investigations of miR-1296 in human cancers and its ceRNA-mediated regulatory mechanisms. This review summarizes the current knowledge of miR-1296 biology and highlights its dual role in cancer, as well as its emerging value as a diagnostic and therapeutic candidate for precision oncology.